1Beach A, Zhang H, Ratajczak MZ, et al. Exosomes: an overview of biogenesis, composition and role in ovarian cancer [ J ] . J Ovarian Res, 2014, 7 (1): 2-14.
2Vaksman O, Trope C, Davidson B, et al. Exosome-derived miRNAs and ovarian carcinoma progression [ J] . Carcinogenesis, 2014, 35 (9) : 2113-2120.
3Szajnik M, Derbis M, Lach M, et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy [ J] . Gynecol Obstet (Sunnyvale), 2013, ( Suppl 4) : 3.
4Giusti I, D'Ascenzo S, Dolo V. Microvesicles as potential ovarian cancer Biomarkers [J] . Biomed Res Int, 2013, 2015: 703048.
5Kan CW, Howell VM, Hahn MA, et al. Genomic alterations as medi- ators of miRNA dysregulation in ovarian cancer [ J] . Genes Chromo- somes Cancer, 2015, 54 (1): 1-19.
6Creighton C J, Hernandez- Herrera A, Jacobsen A, et al. Integrated analyses of microRNAs demonstrate their widespread influence on geneexpression in high-grade serous ovarian carcinoma [ J ] . PLoS One, 2012, 7 (3): e34546.
7Nazarenko I, Rupp AK, Altevogt P. Exosomes as a potential tool for a specific delivery of functional molecules [ J ] . Methods Mol Biol, 2013, 1049: 495-511.
8Li J, Zhang Y, Liu Y, et al. Microvesicle-mediated transfer of mi- eroRNA-150 from monoeytes to endothelial cells promotes angiogene- sis [J] .J Biol Chem, 2013, 288 (32): 23586-23596.
9Cappellesso R, Tinazzi A, Giuriei T, et al. Programmed cell death 4 and mieroRNA 21 inverse expression is maintained in cells and exo- somes from ovarian serous carcinoma effusions [ J ] . Cancer Cyto- pathol, 2014, 122 (9): 685-693.
10Johnsen KB, Gudbergsson JM, Skov MN, et al. A comprehensive o- verview of exosomes as drug delivery vehicles-Endogenous nanocarri- ers for targeted cancer therapy [ J ] . Biochim Biophysica Acta, 2014, 1846 (1): 75-87.
